Narcolepsy is a chronic neurological condition with impairments of the sleep-wake cycle. Narcolepsy manifests with four symptoms, the socalled classical tetrad: a This series of articles focuses on the areas where the mythology may need to be broken and where limitations may not necessarily be recognized. This article has several parts, each interrelated yet independent. As with all publications, information such as this must be considered only after consultation with physicians and any medical information recorded here should not substitute for such consultations.
Diplopia and nocturnal insomnia are two other often ignored common symptoms.
The classical standard narcolepsy research criteria confirming a narcolepsy diagnosis consist of either a positive multiple sleep-latency tests (MSLT), or an abnormally low cerebrospinal fluid (CSF) Orexin (hypocretin) level. I focus on some controversies: a) a) First, the genes for narcolepsy have been largely ignored when applying the recognized criteria for diagnosing narcolepsy. These genes include particularly DQB1*06:02. However, the DQA1*01:02 gene should also be measured 1:02.
b) Secondly, the multiple sleep-latency test (MSLT) may be overemphasized for definitive diagnosis, because the genetic test is as important or even more relevant. This is pertinent because, in the USA, insurance approval of costly medications such as modafinil, armodafinil and sodium oxybate are often dependent on the insurances applying a positive MSLT as a requirement; when it is negative, the insurances might tragically deny coverage of these medications: This might deprive many in the narcolepsy population of their essential life-sustaining treatment, even though they might have definite clinical features plus the gene expression, and often, already, response to wakefulness drugs. c) Third, clinical evaluations must be standardized. At this stage, we, at the PNI b2 apply modifications of the Epworth Sleepiness Scale in conjunction with the Fatigue Severity Scale, and the Neppe Narcolepsy Questionnaire, as fundamental ways to evaluate narcolepsy clinically. These historical rankings and screens combined with proper HLA screening may be adequate for more than 90% of diagnoses.
d) Fourth, the comorbidities of narcolepsy might include psychosis, anxiety, depression, impaired functioning, and seizure phenomena. These may reflect multifactorial etiologies: some of these may be linked with narcolepsy, and others unassociated.
I suggest a new model of hypocretin deficiency being slightly down-stream from the actual cause of narcolepsycataplexy. This accentuates the need for proposing two new terms, namely "primary narcolepsy" for the most common narcolepsy condition that appears to be hypothalamically linked to an auto-immune process involving hypocretin, and "symptomatic narcolepsy" due to infectious or tumor or trauma events involving the hypocretin / reticular activating system/ hypothalamus. On the others hand, some b "PNI" refers to the Pacific Neuropsychiatric Institute in Seattle, WA. "We" is used here to include application at the PNI; "we" is also used generically, for example, in broader recognitions of symptoms by researchers.
The data in this Part 1 points to some key information, yet because it is highly concentrated, some concepts may seem difficult to follow, at this point. But this broad overview might provide a perspective when later on I cover each concept in more detail and accentuate two key points: i) I illustrate specifically a controversy of the gene for narcolepsy largely being ignored, even in the criteria for narcolepsy, and yet a possible overvaluation of multiple sleep-latency test (MSLT) sleep tracings being used for definitive diagnosis. This is important because in the USA insurance approval of expensive medications is often dependent on the MSLT being positive and when negative it might deprive many in the population of essential life-sustaining treatment.
ii) I also emphasize the need for clinical evaluations to be standardized, and point to modifications of the Epworth Sleepiness Scale in conjunction with the Fatigue Severity Scale, and the Neppe Narcolepsy Questionnaire.
Genes
The usual clinician does not have access to such specialized tests, yet every clinician can ask for the Narcolepsy gene test (e.g. the main one is HLA DR DQB2 06:02), and this correlates very highly with Orexin in narcoleptic patients (90% or higher e.g. 92%) [1, 2] . The problem is it has false positives in about one tenth to one third of patients depending on the population.
In our clinical experience spanning over two decades of evaluating such narcolepsy patients, these false positives expressing the narcolepsy gene (usually "DQB 06:02") are not just "control" normal patients. Every one of these controls in our neuropsychiatric population, has had some kind of sleep disturbance. But detailed history shows that these "controls" exhibit lifelong symptoms of different sleep disorders though not clinical narcolepsy. Because other symptoms like depression or anxiety may not be sufficient in many of these cases, it is that likely that many of these patients have other "primary dyssomnias" and often such conditions have not been well delineated. Yet, commonly the families of these "controls with positive narcolepsy gene expression", have classical narcolepsy, also with their HLA "DQB 06:02" gene being expressed.
The utility of genetic testing for narcolepsy was recognized even by 2002 [3] , and the specific HLA DR2 "narcolepsy" gene was reported in 1984 [4, 5] .
But narcolepsy gene testing has remained extremely underrated by many experts who have preferred the far more expensive, specialized, and time-consuming "multiple sleep-latency test" (MSLT) test instead. Yet, in our experience, the HLA typing for the narcolepsy gene can be performed as a simple genetic blood test that provides powerful confirmatory data when used as an addition to the clinical data Indeed, in our experience the gene plus clinical data, as shown later in this article, provides as strong or even stronger diagnostic support than the MSLT test.
More complex testing
Whereas the sleep-onset MSLT, and the Orexin CSF tests are valuable to have available as extras in cases of further diagnostic query after detailed clinical plus gene evaluation, they are specialized because of their costs (MSLT) or invasiveness (CSF) and require specialty involvements.
I know now that narcolepsy is regarded as due to Orexin deficiency [1] in the hypothalamus. This may or may not be an auto-immune process, as sometimes trauma or infection can induce it in predisposed individuals. But that can only be measured using cerebrospinal fluid: So this is not something easily accessible to many clinicians.
Orexin deficiency correlates strongly with the most commonly used standard sleep lab test, the MSLT (possibly 95% ref). The MSLT involves a measure of how often patients go directly into rapid eye movement sleep within say 8 minutes of going to sleep during the day under standard precautions. This is an expensive test, but when it is positive and applied with all its required stringencies, such as not having sleep for (say) six hours before, and not having taken confounding medication, it provides strong support for the diagnosis the narcoleptic condition. Moreover, the MSLT can be applied sequentially to monitor medication responses.. But, there is commonly a tragic problem in the USA. When the MSLT results are negative and yet the clinician based on structured questionnaires, gene testing and pharmacological response regards the narcolepsy diagnosis as definite because these same patients may not be authorized to receive their very expensive wakefulness medications from the insurance company. This is because the insurance industry have taken the criteria of diagnosis of MSLT as the most definitive.
A negative MSLT, in the presence of positive other testing and even medication sample response, is not a rarity, unfortunately, in our experience. This is because only slightly more that one fifth of narcoleptics have a positive MSLT on the first run of the test [6] : Usually 2 such positive tests out of four, five or six, are required. Moreover, some researchers that there are false positive MSLT results: Depending on the population this may be as much as about 3 in 10 positive MSLT cases not even having narcolepsy [7] .
Positive MSLT test results vary with age, specific symptoms in populations, and other confounding factors [1, 8] . Yet, proponents of the MSLT, and this includes most sleep laboratories, claims the MSLT is the most definitive test for narcolepsy, so that this is conflict with the above:
The data suggests that the MSLT cannot be used purely in isolation to confirm or exclude narcolepsy. Many experts believe it is now indicated only in selected patients with excessive daytime sleepiness. And almost every specialist agrees it is most valuable when interpreted in conjunction with clinical findings [7] . It may be that a useful, but as yet unperformed definitive controlled study would be the proportion of patients expressing Clinical features plus HLA-DQ2-06:02 typing who have positive MSLTs and what proportion are of MSLT patients do not express any of the implicated HLA-DQA and DQB genes.
Age
Narcolepsy usually has an onset at an early age (childhood, adolescence or young adulthood), but is often missed till late [9] , the mean delay to diagnosis is up to 15 years, with rare individual cases being delayed even for 60 years, though with education, there might now be a shorter delay to diagnosis.
The delay in diagnosing narcolepsy may sometimes be linked with the frequent association with other sleep-wake disorders [10] .
In my opinion, many cases are never diagnosed. Misdiagnosis or absence of diagnosis is a key problem. Early diagnosis of narcolepsy has the possibility to offer affected persons an adequate medication to lead an almost normal life and the future possibility to cure narcolepsy through immunomodulation therapy [10] .
Comorbidity
Lack of symptom recognition is unfortunate, because narcolepsy has a high comorbidity burden. Many disorders manifest with symptoms that overlap with narcolepsy and patients are labeled bipolar, schizophrenic, depressed and anxious. These detrimental effects impact on proper health-care being used, employment, and quality of life. Education and awareness of narcolepsy and its symptoms might assist [9] .
Moreover, particularly in the young, the symptoms can be disabling enough to interfere with functioning of the child, and therefore compromise his/her education. That in turn leads to further stigmata and impairments.
Men and women have very similar narcolepsy related symptoms. But women may be more likely to be diagnosed later: 85% of men were diagnosed by 16 years after symptom onset (still a long time), compared to a 28 year delay in women (a very long time). One wonders whether the large gray area are those who are undiagnosed [11] .
Interestingly, despite being more objectively sleepy (e.g. on MSLT), women were far less likely to report lifestyle impairments in the areas of personal relationships and physical activity, but were also slightly more likely to self-medicate with caffeine [11] .
However, most important may be a way for clinicians to easily and cheaply make the diagnosis clinically without having to resort to tests such as MSLT, and CSF Orexin levels. This is what this paper is about.
Gold standards
No real gold standard currently exists for the diagnosis of narcolepsy. Conventional diagnostic criteria are unwieldy and arbitrary. Clearly defined criteria for case selection are needed to compare the results of different studies [3] .
However, these criteria require highly specialized evaluations, and therefore are limiting.
Currently, the International Classification of Sleep Disorders (ICSD) Revised 4 represents the research "gold standard" for the diagnosis of narcolepsy. It begins with the classical association of recurrent daytime naps and cataplexy and this has now become sufficient for a definite diagnosis, because the cataplexy symptom is so specific.
But there are many patients without cataplexy, who have daytime sleepiness and other associated features. In a specialized setting, sleep studies may greatly contribute.
The criteria have changed minimally over the years. For example, in DSM 4TR is very close [12] . DSM-V [13] has improved this a little and now recognizes Sleep Paralysis. It also emphasizes co-morbidity of Narcolepsy diagnoses with Schizophrenia and Bipolarity. Whereas, in my opinion, this might be true, it also might not be, because narcolepsy experiences manifest in different ways and may be misdiagnosed. One measure may be pharmacological responsiveness to appropriate neuroleptic, for example, in appropriate dosage [14, 15] .
However, the linkage may be pertinent, as well, in some patients:
Preliminarily, there is a higher frequency of DQ B1(*)-03:01/06:02 antigens in N-C children with narcolepsy and cataplexy who develop what Huang is calling "secondary schizophrenia". This linkage is a therapeutic challenge where there may be long-term persistence of severe psychotic symptoms [16] .
Importantly, diagnoses are also by exclusion so DSM 4R included, as it does for almost every other condition: The classic phrase for all Diagnostic and Statistical Manual of Mental Disorders comments is: "The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or another general medical condition".
Interestingly, at one point, we spoke of narcolepsy, type 1 (with cataplexy) and narcolepsy, type 2 (without). This is really extra verbiage, unnecessary particularly as some have tried to suggest special criteria for qualifying for Type 1 and Type 2-eventually very few would qualify.
Let's now list minima that are usually mentioned
Remarkably there are amazing omissions such as sleep paralysis in the clinical DSM criteria and genetic components in the ICSD criteria. Let's examine this in the light of recent history:
1. Day-time sleepiness frequency at minimum should be at least three times per week over the past 3 months.
2. The presence of at least one of real cataplexy or cataplexy equivalent in children should occur at least a few times per month:
a. In individuals with long-standing disease, cataplectic events can be brief (seconds to minutes) episodes of sudden bilateral loss of muscle tone with maintained consciousness that are precipitated by laughter or joking.
b. In children or in individuals within 6 months of onset, spontaneous grimaces, or jaw-opening episodes with tongue, thrusting or a global hypotonia, without any obvious emotional triggers, are allowed.
3. Recurrent intrusions of elements of rapid eye movement (REM) sleep into the transition between sleep and wakefulness, as manifested by either hypnopompic or hypnagogic hallucinations or sleep at the beginning or end of sleep episodes 4. The disturbance is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or another general medical condition. 
a) The International Classification of Sleep Disorders (ICSD)

ICSD 4R
ICSD 4R is the current gold standard for the diagnosis of narcolepsy and reflects the criteria for the sleep association.
The classical association of recurrent daytime naps and cataplexy is sufficient for a definite diagnosis, the latter symptom being specific. That appears logical.
However, there is a wide spectrum of cases without cataplexy, where daytime sleepiness and other associated features are evocative but not specific, then according to the ICSD polysomnographic studies are mandatory. As you will see in this paper, with due respect, There are confounders with sleepiness in patients with narcolepsy without cataplexy, idiopathic hypersomnia, and Obstructive Sleep Apnea Syndrome creating needs for Interobserver Reliability in the ICSD Diagnostic Criteria for Narcolepsy [17] .
The ICSD-3 of 2014 provides new terminology, classifications, and diagnoses for this disorder that's characterized by daily periods of irrepressible need to sleep or daytime lapses into sleep. This change was made because some patients demonstrate what they consider the fundamental cause for narcolepsy type 1 namely hypocretin deficiency but without cataplexy. The data presented in this article may suggest however that that fundamental cause is an early result of hypothalamic change and that the genetic elements may even be more relevant to causality. I do not see this classification as bringing anything further to the table, except limiting the diagnosis profoundly to MSLT, polysomnography and CSF Orexin, and possibly incorrectly excluding genetic testing, or even pharmacological responsiveness, and excluding most of the population with narcolepsy because they do not qualify on testing.
However, this classification at least widens clinical criteria to include both daily periods of irrepressible need to sleep or daytime lapses into sleep, but may narrow patient diagnosis, in terms of episodes not being daily. This to me, with respect, is problematic.
The ICSD has revised the classification of narcolepsy and this is more sensible: ICSD Revised 4 represents the new gold standard for the diagnosis of narcolepsy. Now the classical association of recurrent daytime naps and cataplexy is sufficient for a definite diagnosis, the latter symptom being specific. On the other hand, if there is doubt, in the wide spectrum of cases without cataplexy, where daytime sleepiness and other associated features are elicited, but not specific, polysomnographic studies are then mandatory.
We can go back in time: There is an extended history across these cultures attributing these symptoms to supernatural causes. These involve entities "incubi" dating back to the times of Martin Luther, or the Newfoundland "Ag-Rog" or "Old Hag" or by the 1970s, "alien abduction". This mythology is usually linked to nocturnal sleep episodes either the sleep paralysis which is non-specific and not diagnostic, or the hypnagogic (sleep-onset) or hypnopompic (sleep awakening) hallucinatory experiences. This may lead to further distressing dynamics, and these beliefs might partly relate to the "true nightmare" [18] . Interestingly, these kinds of interpretations with altered consciousness are not unusual, particularly in a related episodic condition with defect of consciousness, epilepsy [19] . Let's examine both of these briefly:
Narcolepsy
Day Time Sleepiness (DTS)
Daytime sleepiness attacks in narcolepsy involve recurrent periods of an irrepressible need to sleep, lapsing into sleep, or napping occurring within the same day.
One description is "Irresistible attacks of refreshing sleep". Another conceptualization is these attacks are short-lived. Frequently, they may last half an hour and then the patient is refractory to another such attack for several hours e.g. 2 hours. The patient After the DTS attack, the patient feels remarkably refreshed. An essential component of this classical DTS is the episodic element. That differentiates them from chronic maintained states of sleepiness.
The minimum frequency varies for these to be considered narcoleptic: The ICSD requires occurrence at least three times per week over the past 3 months. DSM 4 R required at least daily. More pertinent may be the associated activities: For example, post-prandially an hour after a high carbohydrate lunch, patients prone to hypoglycemia may become sleepy.
Clinically, in narcolepsy, I distinguish between physical tiredness and true uncontrolled daytime sleepiness with the onset or REM sleep.
Nuggets
i) The patient still only sleeps 7 or 8 hours per 24 hours. This means patients have insomnia at night. They do not sleep 7-8 hours at night but less to make up for their micro-sleeps during the day. Narcolepsy is often classified, in my opinion incorrectly, as a "hypersomnia". This would refer to a disorder of increased sleep in the 24-hour day. It is not a hypersomnia, but a "dyssomnia" with breakage of sleep distribution: the disorder of increasing short nap sleeps during the day is countered by insomnia at night to make up the 7 or 8 hours required for mean sleep during the 24-hour period.
ii) Almost every narcoleptic I've seen has had motor vehicle accidents where they've fallen asleep. This is not quite as dangerous as seizure disorders with loss of consciousness when there is no warning. But narcoleptics often can pull over to the side of the road (a few seconds warning) but this is still dangerous, requires medical review, and unless the DTS is excellently controlled these patients should not be driving, and even if well-controlled should recognize that driving is their responsibility and should be for short trips only under medical and prescription supervision.
iii) Therefore, when they take appropriate medicines e.g. Modafinil and Armodafinil they are much better and may not be dangerous. Epileptics are sometimes completely controlled on anti-convulsants and the criterion for driving there varies with jurisdictions e.g. 3, 6, or 12 months or doctor's opinion.
How do I measure the DTS in a clinically standard way? The best way, I think, is applying two scales such as the Modified Epworth Sleepiness Scale (MESS) [20] [21] [22] with the PNI Fatigue Severity Scale (PFISS) [22] . If there are any clues to narcolepsy, such as a MESS score of 10 or more, with a FISS-1 score of 20 or less, we then apply a standardized questionnaire, such as The Neppe Narcolepsy Questionnaire (NNQ) [23] [24] [25] . These are discussed later.
Cataplexy
Cataplexy is a medical condition involving sudden and transient episodes of usually bilateral muscle weakness is accompanied by full conscious awareness. This is due to a sudden loss of muscle tone, and is most often associated with intense emotion (although there are exceptions). The fact that this is bilateral-on both right and left sides together-and occurs in clear consciousness, differentiates cataplexy from seizure disorders.
Cataplectic attacks vary in severity depending on the incident and the individual:
Sometimes cataplectic attacks involve sudden minimal weakness, such as barely perceptible slackening of the facial muscles; alternatively, a cataplectic attack might manifest marked physical collapse with loss of muscle tone and strength, where the body falls helplessly, though remaining conscious.
A basic diagnostic issue is that cataplectic attacks are almost invariably triggered by strong emotions such as laughing, crying, or terror.
Cataplexy affects about 70% of people who have narcolepsy [26] . Occasionally, cataplexy precedes the classical EDS. The extent of severity varies.
Cataplexy as a symptom is sometimes difficult to conceptualize. When trained, raters are "almost perfect" in observing the videotaped physical signs after training [17] . But ordinary mental health specialists don't have that training and don't see such attacks: Therefore a standardized question series such as the NNQ should be useful. Again the NNQ is valuable in this [23, 24] .
Cataplexy manifests as muscular weakness attacks that are brief, and most last from a few seconds to a couple of minutes.
Typically, attacks could involve any or all of dropping of the jaw, neck weakness, and/or buckling of the knees. Complete fullblown muscle paralysis with postural collapse may occur [27] [28] [29] . Speech may be slurred and vision may be impaired (double vision, inability to focus) [30] , but hearing and awareness remain normal.
Cataplexy attacks are self-limiting and resolve without the need for acute medical intervention [27] [28] [29] . If the person is reclining or lying down comfortably, the patient may transition into one of the other narcoleptic features namely, sleepiness, hypnagogic hallucinations, or a sleep-onset REM period [31] .
Cataplexy worsens with fatigue, and it might rarely not be triggered by the usual strong emotional reactions such as laughter, anger, surprise, awe, and embarrassment. Sudden physical effort may trigger it, and being caught unawares or off guard may trigger it or it may be quite spontaneous with no identifiable emotional trigger.
Cataplexy is very varied and more difficult to assess.
It varies from minimal muscle tone-hardly noticed, to major episodes e.g. drop attacks. It often is bilateral, on both sides. Cataplexy may develop only later, particularly when the narcolepsy begins, in children. The cataplexy does not respond as well to Modafinil and requires often something else, e.g. oxybate or tricycles or venlafaxine. Some patients try to avoid emotional situations and these may require prophylaxis.
Almost invariably cataplexy is associated with narcolepsy. Cataplexy without narcolepsy is rare and the cause is unknown.
Even in a collapse, people are usually able to avoid injury because they learn to notice the feeling of the cataplectic attack approaching and the fall is usually slow and progressive. In children, cataplexy and muscle weakness episodes triggered by emotions such as laughing and joking are often atypical. They may be without triggers and affect the face with mouth opening, tongue protrusion. This might occur often with very abrupt sleepiness and weight gain.
As in REM sleep, the person continues to breathe and is able to control eye movements [32] .
Cataplexy presence is almost diagnostic clinically for narcolepsy, yet I have seen a patient with definite cataplexy expressing the HLA DQB1 06:02 gene but with no classical daytime sleepiness, but severe chronic fatigue instead. It could be argued that the daytime sleepiness will come but the fatigue severity in the absence of other conditions is notable.
This would be an example of the value of using a standard clinical measure. The best way is applying a standardized questionnaire, such as The Neppe Narcolepsy Questionnaire (NNQ) [23] [24] [25] . These are discussed later.
Accessory features
Sleep paralysis is regarded as associated with REM sleep atonia intruding into wakefulness. This produces impaired maintenance of REM sleep atonia and might manifest with dream imagery intruding into wakefulness [33] at the start of sleep (e.g. hypnagogic hallucinations) and on awakening (hypnopompic hallucinations). In my opinion, these are often visual and sometimes illusory phenomena, but not hallucinations themselves as they are distortions, not images seen or voices that are heard without any sensory stimulation so the term "hallucination" may be inaccurate sometimes.
Associated features
Attention to periodic leg movements (PLM), sleep apnea and REM sleep behavior disorder (RBD) is particularly important in the management of the older narcoleptic patient, in whom these conditions are more likely to occur [33] .
Differentiating fatigue and sleepiness. Part 3
Fatigue is a general term which refers to any of exhaustion, tiredness, weariness, drowsiness, low energy, sleepiness during the day when you are supposed to be awake.
At the PNI, we have used the PNI Fatigue Severity Scale (FISS) for about 2 decades and found it useful. It is a self-scored evaluation of fatigue designed to differentiate from clinical depression, as both share fatigue symptoms. However, it's also particularly useful as well in narcoleptics to differentiate from sleep apnea and other dyssomnias. We actually use it as part of a series of 10 tests that we call the Diagnostic-Screen 10. The Epworth is another one of these ten tests.
The ratings for the PNI Fatigue Severity Scale (FISS) are based on a 0 to 6 scale (our PNI scoring system) scored over the last week.
There are two tests.
The FISS-1 previously just the Fatigue Severity Scale (FISS) contains 9 items so the minimum score is 0 and maximum is 6.
Range is therefore 0 from 54. Scoring 10 or above is significant. 19 or above reflects problems.
The FISS-1 first item is different My motivation is lower when I an fatigued is scored as a subset decimal point.
Reference is http://www.mult-sclerosis.org/ fatigueseverityscale.html but this scale uses a 1-7 range. This was the only test we used till 2012.
In 2012, the PNI added an accessory 5 point scale-the FISS-2 was added. This was based on feedback from patients and it could be regarded as the activation component. We sometimes combine the scores. This adds 30 more points to the score. We separate the FISS-1 which is the official score, from the FISS-2 which is the extra item score. Our preliminary impression is the FISS-2 might correlate better with features such excessive daytime sleepiness, and also motivational features particularly on awakening. But this needs to be properly analyzed.
Surprisingly, I could not find studies of FISS (here the FISS-1) with ESS. Yet it is logical because patients with many causes for fatigue (systemic e.g., anemia, cardiac, renal, hepatic, Lyme disease; brain related e.g. sleep apnea; psychiatric e.g. depression, anxiety; general e.g. chronic fatigue syndrome) should have their higher FISS scores correlated with the ESS to measure comparative daytime sleepiness. The initial clue for going towards the NNQ is when ESS scores are >11 for narcolepsy daytime sleepiness and also fatigue is only mildly elevated (averaging 1 or 2 per item) as opposed to very high. We have found this clue valuable. As indicated, now, it looks like a relatively high FISS-2 score compared with FISS-1 may also provide an excellent clue to other ongoing investigations. With any of these clues being abnormally high, we then do the Narcolepsy gene blood screen.
There are other approaches as well. For example, The Sustained Attention to Response Task is a valid and easy-to-administer measure to assess treatment effects in narcolepsy, enhanced by combining it with the Epworth Sleepiness Scale [21] .
PNI FATIGUE SEVERITY SCALE (FISS) (FISS-R 2012) © PNI 2012
Name: __________________________________ Date: __________________________ Instructions: This questionnaire contains nine statements that attempt to explore the severity of fatigue symptoms.
Please read each statement and circle a number from 0 to 6. As a guide-line, base your answer on how you've felt over the last week.
A low value indicates that the statement is not very appropriate whereas a high value indicates agreement with the statement.
In the past week:
0 means "I do not have this" ; 1 = this is present but very mild or occasional; 2 = This has been mild; 
FISS -2 total
FISS Grand Total
Measuring sleepiness
The Epworth sleepiness scale (MESS)
This is an 8 item self-scored report. It reflects how much patients fall asleep under normal circumstances, and it is sometimes based on imagining what would have happened.
The original measures on the Epworth Sleepiness Scale (ESS) that we first encountered was 1 (normal, never) to 4, but it appears that is seldom used today, though many publications don't describe what they're using.
We have scored based on 0 to 3 scores with 0= never, 1= slight, 2= moderate, 3= high chance of dozing. The original scale Statistical analysis is much easier when looking at 0 to 3, and this also helps "eyeball" results quickly.
However, we wanted to have a broader severity indication. Therefore we modified the ESS:
All our scoring is 0 for never and applies a 0 to 4 so we apply a 5-point scale. Range therefore 0 to 24. We still obtain two scores so our data can be compared with others using the ESS 0-3 scale. The data in the literature is exclusively the 4 point scale with a maximum of 8*3= 24.
It is here that scores of 11 or 12 are suggestive for narcolepsy particularly if the FISS-1 fatigue score is not very high (e.g. <20). But given that a score of 4 is relatively rare, and would most commonly push the items below 11 or 12, we could technically use MESS R4 in any event.
The MESS and FISS gives us the clue to ask the patient to complete the NNQ below, and whenever we do this for the first time, we perform HLA testing for narcolepsy.
These clinical tools help prioritize individuals with the most severe illness regarding whom we should prescribe medication for. They are not perfect but at least standardized for each patient. We consider polysomnography (PSG) but it is rare for this to be needed because more than 90% of our patients are clear-cut. Additionally, the modern media facilitate reaching out to the general population to raise awareness of the other conditions associated with EDS such as sleep apnea [34] .
And it is this combination, Narcolepsy plus Sleep Apnea, that we see quite frequently.
We return to the ESS: There are over a hundred peer reviews publications on the Epworth in many countries, and translated into several languages.
There is good agreement on all the items totaled together
between the patients and their close relatives, but not always within individual items.
2.
The correlation of objective sleepiness as measured by the ESS and the close relatives is high, and this also correlates on MSLT [35] .
3.
The cut-off for EDS (MESS >10 points) was chosen in line with the traditional ESS.
4.
Data scores before and after interventions correlated with improvement in predicting OSA in patients with COPD [36] .
5.
ESS answers differ according to sociocultural and economic conditions. For example, a score of 8 or higher on the ESS would seem a more appropriate cutoff score than 10 or 11, that many others use, to suspect clinically relevant sleepiness in the Turkish population [37] .
6. Men and women reported similar degree of subjective sleepiness as measured by the Epworth Sleepiness Scale, though women demonstrated significantly more severe objective sleepiness on multiple sleep latency testing (MSLT) [11] .
7. Epworth Sleepiness Scale scores appear to be an indication of personal sleep debt that varies depending on one's individual sleep requirement [38] .
8. Interestingly, ESS scores were considerably more sensitive than MSLT scores in documenting efficacy of the most common treatment, modafinil [20] (and presumably, it would be the same for its very close cousin, armodafinil).
On the other hand, the improvements in MSLT scores were minimal and remained in the pathologically sleepy range [20] . These findings suggest that the ESS is a more sensitive and clinically meaningful tool to evaluate the efficacy of modafinil in narcolepsy [20] .
9.
By measuring a clinically useful and well-used fatigue scale, the FISS-1, we are able to better gauge the relevance of the patient's sleepiness at a clinical level. Although we have added the FISS-2 to it, and cannot officially analyze it because there is no other standard for these questions, we have found that it is clinically useful appreciating the success of the interventions because the real world seldom contains a single individual diagnosis.
We now list our version of the MESS-R. At this point, any collaborations would be excellent for this and the PNI-FISS. We also welcome clinicians at this point using this in their practice provided they let us know at admin@pni.org that they're doing so.
Modified Epworth Sleepiness Scale (MESS-R) © PNI 2016
NAME: ______________________________________________ DATE: _____________
Please between 0 and 4 for the degree (how much?) it's been happening in the past week. Please do not write here:
MESS R3 Score (1-3) = ; MESS-R4 score =
The Neppe Narcolepsy Questionnaire (NNQ): Part 4
The Neppe Narcolepsy Questionnaire (NNQ)
The Neppe Narcolepsy Questionnaire is a copyrighted screening questionnaire [25] . This developed out of necessity because as far as we're aware there is now equivalent.
It was needed in the running of the Pacific Neuropsychiatric Institute (PNI), as it would be for any Neuropsychiatric Institute.
Vernon Neppe authored an early version of this test in the 1982 while working in a Sleep-Wake Lab at the Division of Chronobiology, Cornell University, NY. Dr Neppe then adapted it in the early 1990s. This has become critically important because there remains no test to screen for possible narcoleptic symptoms [23] . Recently, Dr Neppe updated the NNQ (2016) to include the latest criteria and ideas on narcolepsy and cataplexy. These were purely additions, with no subtractions so that our previous dataset remains.
The NNQ has been used regularly clinically (at the PNI) since 1992 for all patients in which the diagnosis of Narcolepsy or a narcoleptic syndrome is queried. We cannot present comparative data because there is no other questionnaire. But it has proven extremely sensitive and specific in screening for symptoms of Narcolepsy based on measures of diagnosis and also of clinical response to medication. (In twenty years we have not had patients where eventually we prescribed wakefulness agents and found the patients did not respond as expected. On the other hand we did not use these agents when not indicated, and managed with alternative medications. We can therefore argue that the use of the NNQ is proven.
In practice, the NNQ has always been combined with the HLA Narcolepsy screen and HLA-DS15 (DRB1*15), HLA-DQ6 (DQA1*0102/DQB1*0602). This has proven useful in supporting our expectations (clinical hypotheses) that the NNQ is valuable. As a point of interest, at the PNI, we might see more narcolepsy than anywhere else in WA state. Consequently, we have over the past two plus decades had the opportunity to see many variants. At times we see more patients because of loaded family histories. Our comments here are based on this experience.
The NNQ together with HLA have proven very useful. The utility is well documented on response to appropriate medications particularly wakefulness agents, such as Modafinil. Usage of these criteria differentiates two groups: A Narcolepsy diagnostic group and a Primary Dyssomnia (without Narcolepsy) syndrome.
Interestingly, a high proportion of these patients has temporolimbic instability and also require anticonvulsants.
I provide below the key aspects of the NNQ. Those wishing to use it in research or clinically should contact us at admin@ pni.org.
Neppe Narcolepsy Questionnaire-4R (NNQ-4R) [25]
I. SLEEP HABITS: Indicate this proportion unpleasant to pleasant.
2. Do you find that during these experiences you have any particular thoughts?
Describe.
3. Do these experiences seem to lead on from any particular kind or dream?
Describe. 
V Special tests:
Please give the results of any of the tests you've had relating to sleep difficulties. 
VI. Automatic Behavior
IX Dreams
For all the following experiences, indicate whether they occur during daytime naps or during the night, so that they are in fact two series of answers: The Genetics of Narcolepsy: Part 5
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No gold standard currently exists for the diagnosis of narcolepsy. Conventional diagnostic criteria have often been unwieldy, requiring low CSF orexin (same as "hypocretin"), or 2 positive SORMPS out of 4 or 5 or 6 under strict MSLT conditions. The criteria are often arbitrary and varies. Yet, in research, defined criteria for case selection are needed to compare the results of different studies [3] . Even more so real interpretation is required clinically.
Most importantly, it seems that based on the data available, we can ensure a diagnosis of narcolepsy that is appropriate in the high 90% range. This can be easily done by clinically applying careful evaluations and structured questionnaires. This allows making sure the patient's day-time sleepiness conforms to the narcolepsy label, that the patient has cataplexy features which makes the diagnosis more specific, and that the patient expresses HLA DQB1*0602. If this happens, and this triad of features based on research occurs in some 85% of cases, we can be reasonably certain that the patient will also have a CSF hypocretin/ orexin deficiency. We will therefore know the cause biologically is due to the disease state of narcolepsy. This data is not new, but has been known since 2002 [3] .
MSLT may be valuable in the small proportion of patients who fail in this assessment: this will include either or both of narcolepsy without cataplexy, or those who do not express HLA DQB1*0602, but they might even include those who on CSF do not have a hypocretin state. I humbly submit that at this point, these exceptions are at best unproven entities and that biologically they might not be narcoleptic and may reflect more than one condition or subtype. Yet, we don't have studies, at this point, proving different conditions or subtypes.
Let's look at the information available on the HLA gene. We know that:
Even as long ago as 2002, new research diagnostic criteria for narcolepsy were based on HLA typing. These possessed high interrater reliability and appeared valid descriptors of the syndrome. These results may be useful in providing consistent criteria to compare different research studies [3] . Why?
ii) The key, most common gene involved in narcolepsy is HLA DQB1*0602: depending on the study, about seven eighths [39] or even 12/13 [1] of cataplexy patients, but only 33% of those with narcolepsy features without cataplexy, express the gene [3] . The question is: Are these figures of the those who do not express the correct HLA gene reflecting poor clinical diagnoses and not representing narcolepsy, or are they accurate? Clinically, this is unanswered completely, but they likely accurately reflect different diagnoses based on rankings of narcolepsy diagnoses [3] . Why?
iii) The HLA-DQB1*02 frequency is also increased in the population with hypersomnia when compared with the control population (p = 0.004) But enough with hypersomnia without narcolepsy are positive that we need other tests. This means effectively that the *0602 expression reveals potentially more than narcolepsy and therefore that it may encompass any dyssomnia. My own impression is that if one is very careful in a neuropsychiatric population: We have found that even those "controls" who express *0602 have, in every case, expressed some kind of sleep disturbance. A 34% figure of "controls" from this study [40] . is the highest in the literature [3] with 16% being a more common estimate [40] , and there may even be only 10% or less so-called false positives depending on the population [23] . I argue that the difference is an epidemiological one, depending on how skewed and symptomatic the population is. But, I humbly submit that we could be talking about the far more common "primary narcolepsy", with the usual gene expression, and if tested this would imply low orexin and likely autoimmune components, and "symptomatic narcolepsy", with secondary brain damage at the hypothalamic RAS level. This can manifest in many ways: I've even seen a case mobilized by cysticercosis.
iv) The evidence is so strong that if DQB1*06:02 is positive, subjects are at a 251-fold increase in risk for narcolepsy [41] ! An overwhelming portion of genetic risk for narcolepsy with cataplexy is found at this DQB1 locus [41] , but importantly other loci such as DQA may also be relevant and therefore tests should be for both loci, particularly as expression at both loci might show higher penetrance of symptoms.
v) Without HLA-DQB1*02 expression, it is very unlikely that narcolepsy exists [40] . My impression is that, yes, narcoleptic syndrome could exist but this is due to possible damage to the Orexin or hypothalamoreticulo-activating system dysfunction due to trauma, tumor or infection. So the absence of genes does not then exclude narcolepsy, but the clinical situation must provide much stronger evidence.
vi)
We generally need not demonstrate low CSF hypocretin-1 levels. This is because we know, based on other research, that low hypocretin will likely be present in about 85% of cases with DQB1*06:02 expression and cataplexy. However, if the patient does not have cataplexy, only about one fifth of such patients will have low CSF hypocretin-1 levels: This is a curiosity, because cataplexy sometimes takes some years to develop after the narcolepsy day time sleepiness. This might mean that the low CSF hypocretin-1 levels are not primary but secondary to progression of the illness.
vii) However, rare cases (about one in sixty) are DQB1*06:02 negative with low CSF hypocretin-1. These occur equally with or without cataplexy: Therefore, even hypocretin does not correlate fully. There are rare HLA negative subjects with severe cataplexy, but often without clear triggers [39] . This might suggest that another gene could be involved, so we need to look further here.
viii) Although HLA-DQB1*06:02 is the strongest predisposing genetic factor for narcolepsy, the effect of this gene must therefore be considered alongside that of others, and that turns out to be its polymorphic partner, DQA1 [39] . ix) HLA-DQB1*06:02 allele with narcolepsy and cataplexy is clearly a major predictor of cataplexy in narcoleptic patients. We argue that the literatures' supports it could be used as an additional diagnostic marker alongside Hypocretin [42] . This may seem obvious but bears mention because the literature seldom points this out.
x)
The genetic basis for narcolepsy may also be linked increased susceptibility to infectious factors or an immune cytotoxic mechanism in narcolepsy, potentially targeting hypocretin neurons: this may be linked not only with DQB1 gene but DQA [43] .
xi) A secondary HLA-DP association may be present in rare cases representing particularly difficult diagnostic challenges: The rare subtype DPB1*0901, and homologous DPB1*10:01 subtype [39] . However, it does point out that occasionally there are other ways of narcolepsy expression.
xii) The HLA-DQB1*06:02 involves a functional HLA-DQ molecule consists of a DQ alpha and a DQ beta chain. The HLA-DQB1*06:02 (DQ beta) has a strong preference for binding to HLA-DQA1*01:02 (DQ alpha ), and together they form the functional DQ0602 dimer [44] .
xiii) In individuals homozygous for HLA-DQB1*06:02-DQA1*01:02, a dosage effect would be expected if the HLA-DQ0602 dimer itself is directly involved in the etiology. This does occur. An increased expression of the HLA-DQ0602 dimer is expected in individuals homozygous for HLA-DQB1*06:02-DQA1*01:02, but is also hypothesized in individuals heterozygous for HLA-DQB1*06:02 and homozygous for HLA-DQA1*01:02. A Dutch study showed importantly, a significantly higher prevalence of homozygosity for DQA1*01:02 was found in HLA-DQB1*06:02 heterozygous patients compared to controls (O.R. 2.37, p < 0.001). The latter finding clearly supports a direct role of the HLA-DQ molecule in the development of disease. 44 It also suggests that all studies should include DQA1*01:02 as well as DQB1*06:02. This is supported by other genetic studies [45] .
xiv) HLA genes likely function under an incomplete penetrance model, with possible influences from environmental factors or other genes different to HLA genes [46] . This may explain why patients from the same family, and with the same main gene expressions like 0602, still vary markedly in symptoms. 46 At least some of these patients have markedly loaded family histories and autosomal dominant inheritance is likely [47] [48] [49] .
xv) Few sleep disorders have an established genetic basis including four rare diseases that may result from a single gene mutation: fatal familial insomnia, familial advanced sleep-phase syndrome, chronic primary insomnia, and narcolepsy with cataplexy. However, most sleep disorders are complex in terms of their genetic susceptibility together with the variable expressivity of the phenotype even within a same family [50] . The extent of penetrance of genes is pertinent here.
xvi) Finally, reanalyzing the genes, it may be even more complex. There may be protective genes based on Chinese work. HLA-DPA1(*)01:03-DPB1(*)04:02 (DP0402; [51] . They also found an independent predisposing effect of DQB1*03:01 predisposes via a currently unknown mechanism which might explain the few that are not due to the 06:02 gene. They also reported strong protective effects of HLA-DPA1(*)01:03-DPB1(*)04:02 (DP0402 and HLA-DPA1(*)01:03-DPB1(*)04:01 (DP0401 and predisposing effects of HLA-DPB1(*)05:01 [52] . It is clear that both DQA1 and DQB1 influence narcolepsy risk [51, 52] . xvii) Moreover, genome wide association studies have subsequently been able to prove that autoimmune mechanisms are responsible for the manifestation of narcolepsy with the HLA association being the most important for susceptibility and protection [10] .
xviii) Unlike the case of canine narcolepsy, where mutations in the hypocretin (orexin) neuropeptide precursor (HCRT) receptor have been found, it has been argued that Orexin deficiency is the cause of human narcolepsy [31, 53] . The recent advances in the elucidation of the genetics of canine narcolepsy and the pathophysiologic role of hypocretin, in animals and humans, enhances current diagnostic capability and will ultimately provide better treatment modalities in the future [27] , as well as clarify etiological and diagnostic issues.
xix) Data also suggests that narcolepsy may be the result of an autoimmune reaction triggered by H1N1 vaccination in susceptible individuals [54] .
xx) Given these differences, and the above data, it might support the possibility of HLA genes and associated receptor expressions being fundamental.
xxi) Moreover, Mignot's analysis could explain increased disease heterogeneity in a non-cataplexy group and a direct effect of the HLA DQB1*0602 genotype on the clinical expression of narcolepsy supports this [55] .
xxii) Based on this data, it appears that the gene expression may be even more basic than the low orexin / hypocretin levels which may be secondary: This is a new Neppe hypothesis using this data. Effectively, the current idea has been that hypocretin deficiency causes the narcolepsy. I propose that based on the HLA data the cause is higher up the stream, and orexin deficiency is a consequence, albeit an early consequence downstream, but not a cause. A way to test this is to find patients with HLA DQB1 * 06-02 gene expression, with any early symptoms of narcolepsy, but which has normal orexin, and then with progression, later deficient orexin.
Nuggets
a. Further characterization of the HLA genes could potentially enhance differential diagnosis among those expressing different kinds of excessive daytime sleepiness and this may correspond with diverse entities with different biological mechanisms [40] . But this is too specialized. Let's just remember the rules, not the exceptions.
b. We must test both for the DQA and DQB genes. A recent and changed but common habit, certainly in our geographical area, is labs just doing the HLA-DQB1*06:02. This misses the other genes involved and may provide insufficient data for clinical assessment and later comparative clinical research, too. At minimum, DQA1*01:02 should be performed.
c. In my experience over the past 20 years, in my neuropsychiatric populations, every patient expressing the gene has on careful analysis had some kind of dyssomnia: This is not a "normal" control population by any means.
Management of narcolepsy: Part 6
Two conditions are treated in narcolepsy.
The first is day-time sleepiness.
Current treatment recommendations suggest that these wakefulness drugs (also called wakefulness-promoting agent or eugeroics) should be used as a first-line treatment ahead of conventional stimulants such methylphenidate or sodium oxybate [56] .
The advent of modafinil (Provigil in USA) and armodafinil (Nuvigil in USA) (it's daughter effectively with a longer half-life allowing daily not BID management at times) has revolutionized management of narcolepsy [57] . It is indicated for narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea [58] . It is not indicated in cataplexy.
Modafinil and Armodafinil is a schedule IV controlled substance with restricted availability and usage in the USA, though in many countries it is a prescription drug, but not further controlled.
Although the mechanism of action of modafinil and armodafinil was initially unknown, we do know it does act as a selective, relatively weak, atypical dopamine reuptake inhibitor, possibly as a dopamine transporter reuptake inhibitor [57] .
Modafinil produces wakefulness reportedly without the need for compensatory sleep, and shows a relatively low, if any [59] , potential for abuse, through mechanisms e.g. cholinergic may be pertinent.
What is useful in follow up is the ability of sleep-stage sequencing of sleep-onset rapid eye movement periods in the multiple sleep latency test to predict treatment response, in narcolepsy, with cataplexy or without, applying clinical and polysomnographic criteria. This can be used in monitoring response to medications [56] . However, as indicated, the Epworth Sleepiness Scale appears more effective when using modafinil in narcolepsy [20] and also in obstructive sleep apnea [36] .
The second medication approach is in the management of the Cataplexy.
Sodium oxybate and gamma-hydroxybutyrate has been found to be effective at reducing the number of cataplexy episodes. Sodium oxybate is generally safe and typically the recommended treatment for some clinicians as the most effective agent.
Sodium oxybate (USAN) (Xyrem from Jazz Pharma USA) is designated as an orphan drug, a pharmaceutical drug developed specifically to treat an orphan disease, cataplexy and narcolepsy. It is FDA approved for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy, and for the treatment of cataplexy associated with narcolepsy. and under the name Alcover, it is used in Italy for treatment of alcohol withdrawal and dependence. Therefore, it's the only drug marketed for narcolepsy EDS and cataplexy. It is generally well tolerated by most patients. The drug has been safely used by patients with narcolepsy since 2002, with surprising low rates of abuse, dependence, and withdrawal, and very rare sexual assault cases.
The active metabolite of sodium oxybate, gammahydroxybutyric acid, acts as an agonist at the GABA-B receptor complex and the GHB receptor. This likely contributes to some part of sodium oxybate's therapeutic effects.
However, it is a central nervous system depressant and must be taken exactly as prescribed. My biggest problem with oxybate is a practical one: patients must take it at night and wake in the night to take the second dose. A lesser irritation is simply that and patients should not eat for two hours before bedtime.
Instead, my own preference is for tricyclic antidepressants. I have been using nortriptyline but others use imipramine, clomipramine or protriptyline; venlafaxine is possible, although it can be argued that the benefit is not as good. I have seen recommendations pertaining to SSRIs, but I have no proof all are effective, and if so that the effect will be maintained for prolonged periods. Because tricyclics have been available for up to 60 years, we know they do not appear to lose efficacy certainly in depression.
These compounds work to manage both cataplexy and the REM sleep-onset symptoms of sleep paralysis and hypnagogic hallucinations.
Non-pharmacological management
Non-pharmacological management of narcolepsy is important: Patients should maintain a strict regular wakesleep schedule and good sleep hygiene. They should benefit from voluntary afternoon naps and a program of regular exercise [33] . Importantly, many cataplectics try to avoid highly emotionally charged situations such as laughter.
Treatment is highly individualized, depending on the severity of daytime sleepiness, cataplexy and sleep disruption.
Nuggets
Patients with narcolepsy should respond to modafinil or armodafinil. Dosage varies greatly.
Patients with cataplexy need tricyclic antidepressants like nortriptyline in low to medium doses.
Patients with hypnagogic hallucinatory phenomena sometimes respond to small doses of atypical neuroleptics like aripiprazole 2mg to 5mg daily (but this is an out of label use).
Mechanisms of narcolepsy: Part 7
The current postulated cause of narcolepsy is due to an autoimmune destruction of the neurotransmitter hypocretin, which regulates arousal and wakefulness. This leads to a low level of CSF hypocretin. We know further that damage to orexin-secreting neurons in the hypothalamus can lead to inhibition of motor neurons, thus lowering muscle tone.
Cataplexy
The neurological process behind the lesion of narcolepsy is the impairment of descending pathways controlling the normal inhibition of muscle tone, consequently, cataplexy results with muscle atonia [60] .
This loss of tonus is caused by massive inhibition of motor neurons in the spinal cord. When this happens during waking, the victims of cataplectic attacks lose control of their muscles.
However, even though it is not apparent, muscle tone paralysis occurs at inappropriate times, but, nevertheless, the patient still continues to breathe and is able to control eye movements [61] . This is postulated and likely to be because this phenomenon is linked with Rapid Eye Movement (REM) sleep.
The hypothalamus region of the brain regulates basic functions of hormone release, emotional expression and sleep. The absence of neuro-excitatory properties of the hypothalamic hypocretin-peptidergic system 33 appears linked with the neurochemical hypocretin (Orexin), which is regulated by the hypothalamus. Hypocretin is significantly reduced in almost all patients with the symptoms of cataplexy, and is the primary chemical important in regulating sleep and states of arousal. Hypocretin deficiency is further associated with decreased levels of histamine and epinephrine, which are chemicals important in promoting wakefulness, arousal and alertness.
Substitution of the deficient neuropeptides by hypocretin agonists [62] is a possible causal treatment strategy if this is, indeed, the etiology, or even if this is an early result of cataplexy and EDS.
The reticular activating system
The reticular activating system involves up and down stimulations [63] .
The muscular paralysis can be perceived as the reverse effect of the sleepiness. The Reticular Activating System (RAS) goes to sleep in the other direction at an inappropriate timeso to say when RAS phenomena occur upwards. When this upward component happens during waking, we argue that the patient falls asleep and the kind of firing results in rapid-eyemovement sleep almost immediately with or without stage 1 sleep.
When the downward component happens during waking, the patient with a cataplectic attack loses control of some of their muscles [32, 63] . This loss of tone is caused by massive or limited inhibition of motor neurons in the spinal cord.
Hypocretin deficiency
Hypocretin levels can be measured using cerebrospinal fluid (CSF) hypocretin-1 immunoreactivity values: Deficiency is currently regarded as a level of less than or equal to onethird of values obtained in healthy subjects tested using the same assay, and this usually works out to less than or equal to 110 pg/mL. Nevertheless, some argue that the optimal cutoff of CSF hypocretin-1 for narcolepsy without cataplexy diagnosis should be as high as 200 pg/ml rather than 110 pg/ml. [64] . A limitation is that CSF levels of hypocretin-1 should not be assessed in the context of acute brain injury, inflammation, or infection.
Patients with narcolepsy possess a reduced number of hypocretin-producing neurons in the hypothalamus and accordingly the hypocretin level in the cerebrospinal fluid is low [10] .
Anatomically, hypocretinergic axons make asymmetric synapses with neurons within the locus cerulean, ventral tegmental area, dorsal raphe nucleus and laterodorsal tegmental nucleus that target the medial frontal cortex. Hypocretins could facilitate wakefulness and cortical activation, therefore, by activation of those neurons with cortical projections in these four reticular nuclei [65] .
The neuropeptide hypocretin (orexin) has functions, such as the regulation of the sleep-wake cycle, the autonomous nerve system, motor system and metabolic processes [10] .
Imaging studies have revealed neurodegenerative changes, making a multifactorial etiopathogenesis probable. The frequent occurrence of metabolic disorders has not yet been clarified. 10 And certainly puzzling are those few cases with normal hypocretin levels in the CSF. Does this imply a second process such as resistance to the receptor, or another cause, or as indicated, that the hypocretin deficiency certainly is an important result, but minimally downstream and not the primary etiology.
How do low hypocretin patients compare with normal hypocretin measures on NPSG and MSLT? These patients have far more frequent short rapid-eye movement (REM) sleep latency during polysomnography, as well as shorter sleep latencies and more sleep-onset REM periods during the Multiple Sleep Latency Test (MSLT) [64] .
In essence, current thinking is that measuring CSF hypocretin-1 is a definitive diagnostic test, provided that it is interpreted within the clinical context [66] . It has limited use when the MSLT is difficult to interpret as in subjects who are already treated with psychoactive drugs or with other concurrent sleep disorders [66] .
Nugget
The question is "how far down in the narcolepsy cycle is the orexin data"? A small proportion of cataplectics have normal orexin levels yet express abnormal DQB genes [67] . Could it be that the damage is reflecting hypothalamic abnormalities and, as seen in the HLA discussion, based on this data, it appears that the gene expression may be even more basic than the slightly downstream low orexin / hypocretin levels, which then may be secondary? In this paper, I have suggested this as a feasible and possible new hypothesis, because the HLA data as a whole supports this line of reasoning.
Multiple Sleep Latency Test (MSLT): Part 8
The Multiple Sleep Latency Test (MSLT) test has become a routinely recommended evaluation to be performed in Sleep Labs for the diagnosis of narcolepsy [68] .
Without doubt, the test has some strong virtues in assisting difficult diagnoses and in monitoring changes after treatment, but that must be put in a perspective. The problem might be more complex. MSLT is expensive, and when narcolepsy is diagnosed or suspected, but MSLT does not prove the condition, then often the insurance companies will not approve the costs of wakefulness drugs treatment, which on an extended lifetime basis, using today's prices, is extraordinarily expensive. If this happens, patients may not be able to afford their treatment and they might deteriorate, be unable to work, have disruptive family lives, and suffer a great deal and compromise their families. And therefore, if they have a narcolepsy diagnosis, and are already responding to modafinil or armodafinil, this creates a major risk for them, as their medical record might say that they do not have a positive MSLT. That is potentially tragic.
In other words, I argue that there must another acceptable route for the medical insurances in the USA, certainly, to approve what the treating physicians regard as appropriate diagnoses of narcolepsy with or without cataplexy, when these patients have been evaluated even without MSLT. That acceptable route should be clinical and scoring data e.g. Epworth, plus NNQ or other historical standard protocol, plus expression of HLA-DQB-0602.
The problem may be more insidious. Why not just get an MSLT even though the diagnosis is relatively certain, including marked family histories? The difficulty is the "normal" MSLT result because at that point the patient who merits treatment on the basis of the previous narcolepsy evaluation (as listed in the sixth point above) may be denied costly pharmacological interventions by the medical insurances, and may not be able to afford the medications. This can be catastrophic for their future. Sadly, we personally have seen this happening on a number of occasions, and see as this as very tragic: Patients have literally lost their livelihood because they could not work and the insurances would not approve what for them are lifesaving medications.
Additionally, as Mayer points out, the MSLT is a poor gold standard [69] .
Effectively, the ICSD-4 is, in any event, easily applicable in cases with typical cataplexy and narcolepsy where with the MSLT, further evaluations are almost always positive and may thus not always be needed [1] . The main conundrum lies with patients without cataplexy who are difficult to classify [1] . These patients' results might demonstrate difficulties in interpreting the MSLT, particularly in the presence of sleep apnea or reduced sleep.
Let's briefly examine the utility of the Multiple Sleep Latency Test (MSLT).
The most common criteria used is a multiple sleep latency test involves examining for Sleep Onset Rapid Eye Movement periods (SOREMPs). The MSLT test consists of four or five or even six 20-minute nap opportunities set two hours apart. The patient is monitored to measure the time elapsed from the start of a daytime nap period to the first signs of sleep and sleep latency. For a SOREMP to be positive, it should showing a mean sleep latency less than or equal to 8 minutes. For an MSLT there should be two or more SOREMPs. Technically, therefore, there should be two episodes of almost REM onset sleep for diagnosis or close to that, with up to a few minutes of a little stage 1 sleep beforehand, being acceptable. This criterion might be too stringent and diminish yield, but if there was only one SOREMP that might be too easy. This view is supported: Dauvilliers argues that the MSLT criteria indeed are too stringent certainly in the older population [8] .
An alternative that counts for one SOREMP in the American Academy of Sleep Medicine (AASM) classification, is a SOREMP (this time showing latency to rapid eye movement (REM) sleep of less than or equal to 15 minutes of sleep onset) on the preceding nocturnal polysomnogram (PSG) and this may replace one of the SOREMPs on the MSLT. Nocturnal polysomnography (NPSG) sometimes precedes they multiple sleep latency testing (MSLT).
The NPSG of a narcoleptic patient may be totally normal, or demonstrate the patient has a short nocturnal REM sleep latency (suggesting narcolepsy), or the patient may exhibit separate unexplained arousals or periodic leg movements [33] .
Based on sleep wave measurements, the diagnosis of narcolepsy is therefore supported by the presence of two or more sleep onset REM periods (SOREMPs) in the MSLT, or sleep onset REM periods (SOREMPs). Let's re-examine this.
Sansa et al examined the distribution of SOREMPs throughout the MSLT in narcolepsy with and without cataplexy. They applied the common five-nap test in MSLT, which requires at least two such tests to be positive. On average, about one fifth of these nap tests showed SORMPS and the fourth test in that sample was about a sixth. Shortening the MSLT to three or four naps decreased the capability of the test even more to support the diagnosis of narcolepsy [6] .
Sleep laboratory testing should be performed according to standard techniques, and results should be carefully interpreted in the context of the patient's clinical history in the presence of EDS. At least 1 week of Actigraphy assessment with a sleep log is strongly recommended prior to MSLT to determine factors that may bias results (e.g., insufficient sleep, shift work, or other circadian rhythm disorder). These reflect stringencies in the MSLT procedure (as behooves any logical test), for example, the patient should not have slept less than 6 hours prior to MSLT, and the issues of medication will vary: for example, on what one is monitoring e.g. response to treatment is one parameter.
Hypersomnolence and/or MSLT findings should not be better explained by other causes such as insufficient sleep, obstructive sleep apnea, delayed sleep phase disorder, or the effect of medication or substances or their withdrawal.
On the other hand, in another study, patients with definitive orexin findings, and proven narcolepsy with cataplexy, have much higher sensitivity of 96% with specificity of 74%, whereas two SOREMPs had a sensitivity of 75%, with a specificity of 95% for a pathological REM sleep propensity at MSLT. In this population, which likely does not require clinical selection at all because it is definitive, the multiple spontaneous SOREMPs during daytime clearly identified patients with narcolepsy [68] .
MSLT can also prognosticate: The presence of this specific sleep-stage sequence in all sleep-onset rapid eye movement periods was associated with worse treatment response and aid the prediction of treatment response in narcoleptics and provide a useful prognostic tool in clinical practice [56] . However, we could logically hypothesize that simply monitoring severity of clinical episodes e.g. by Epworth score, or the presence of HLA genes both DQA and DQB [46] , or pharmacological response, might provide an even more adequate monitoring test, as well, but the research has not adequately explored that.
These tests MSLT, Orexin, HLA are controversial in their interpretation: As I regard the literature currently including much of the research, routine MSLT is not required to prove diagnoses of narcolepsy when clinical (including structured histories) and HLA confirmation confirms the diagnosis of both narcolepsy and cataplexy. Technically, classifications have varied with what has been called Narcolepsy Type 1 involving both excessive daytime sleepiness (EDS) and cataplexy as core features, and Narcolepsy Type 2 requiring the excessive daytime sleepiness as the essential feature but where cataplexy is absent. These criteria seem reasonable except one can say ""Narcolepsy with Cataplexy instead of Type 1, and "without Cataplexy" instead of Type 2. The problem comes when some classifications add additions such as MSLT and / or CST orexin as mandatory criteria: Those additions exclude most conditions from being either Type 1 or Type 2 because those tests have not been done. Additionally, if we examine the literature carefully, it is astonishing that HLA testing for narcolepsy has just been excluded in almost every list of fundamental criteria.
Without cataplexy, MSLT for narcolepsy may be useful but should not be overvalued because it is not a gold standard, as in the real world there are often complicating features, such as additional obstructive sleep apnea. 
Perspective on narcolepsy and cataplexy: Part 9
This final section is best illustrated with tables. First, I describe, again, the classical narcolepsy quartet where daytime sleepiness and cataplexy are far more important clinically than the other symptoms which may be non-specific and so not diagnostic and are difficult to conceptualize.
Day-time sleepiness:
This involves uncontrolled sleepiness. Very commonly has a history of falling asleep while driving. After a 20 minute nap with or without remembered dreams, there is an episode of several hours of refractoriness during which the patient is very refreshed.
Cataplexy: This loss of tone often occurs with high emotion. It can involve small groups of muscles and sometimes involves dropping objects, or the knees buckling. It can manifest with any group, but in our experience may be consistent for that individual. Cataplexy is very common and leads to a classification of Narcolepsy with cataplexy and Narcolepsy without cataplexy.
Sleep paralysis: This is likely associated with the hypotonia in REM sleep with awakenings. The patient awakens from sleep during the night, was in a REM phase, and cannot move because he/she continues to be hypotonic. But respiration is ostensibly unaffected, and eye movements can occur, and males may be erectile. Patients should be reassured about the mechanism and that they are not safe during these episodes and not about to die, because such happenings otherwise could be very frightening.
Hypnagogic and hypnopompic phenomena: Again, hypnagogic experiences may be linked up with the onset of REM prior to fully sleeping. I seldom encounter hypnopompic phenomena. These both are often predominantly visual, do not respond to atypical neuroleptic, and involve more distortions with illusions than hallucinations. The patient may have had them before, and education about them can take away the sense of fright, they may otherwise experience. Next I describe features that are often not asked about. Double vision is again non-specific, but so is insomnia. However, the insomnia is a key symptom if patients are having narcoleptic sleepiness during the day, they must have insomnia. Therefore, treatment for insomnia at night with medications must be carefully considered.
The difficulty with narcolepsy is the concurrent morbidity.
Often the hallucinatory (usually visual) episodes or visual illusory distortions are misinterpreted. Patients are then given high doses of neuroleptic and get worse. Some end up in mental hospitals, sometimes for prolonged periods, because they get worse. And they are theoretically far more likely to be at higher risk then for tardive dyskinesia because they are biologically receiving inappropriate doses of neuroleptic for what are not true psychoses [14, [72] [73] [74] [75] .
Psychotic or psychopathological features:
This occurs in about a quarter of patients and manifest differently from what one would expect. Narcolepsy is the great mimicker and we have several patients who were misdiagnosed and even may have ended up in mental hospitals [23] .
Primary Dyssomnia. Commonly we see patients with gene expression and often with a loaded family history, yet no history of narcoleptic symptoms. Yet, we have never seen a patient who has no sleep disturbance after taking a detailed history, and yet this genetic expression. This leads us to postulate that there is a gene positive, primary dyssomnia group who manifests extreme fatigue, yet still responds to wakefulness drugs. The genetic expression is, therefore. non-specific primary dyssomnia with narcolepsy as the primary condition, but never in our experience has the patient been entirely without sleep disturbance. But then we do not evaluate "normal" individuals, usually so this is a biased population! [23] Strange experiences: Though claimed otherwise, we have not seen more patients than the average population with out-of-body [76] , near-death, or subjective paranormal experiences [23, 77] . Importantly, these are often not recognized.
Diplopia: Double-vision is a common accessory symptom. But eye movements should be spared and this therefore should not be associated with cataplexy, so the symptom is strange [23, 30, 70, 71] .
Nocturnal insomnia: This is very common and classically explained by the narcoleptic still having 7-8 hour per day sleep cycles but their micro-sleeps during the day produce less need for sleep at night [23] . d. We've seen two patients who are MSLT positive and yet genetically negative. This suggests there is more to Narcolepsy than just the gene, as well.
Pharmacological measures
a. Invariably these patients respond to Wakefulness agents such as modafinil, armodafanil and sometimes to psychostimulants, partly and incompletely such as methylphenidate on its own, or as adjunct to the wakefulness drug.
b. Unlike the early literature that claimed that the electroencephalogram is invariably normal, about half our patients with narcolepsy have temporal lobe foci, or are loaded with temporal lobe symptomatology and respond to anticonvulsants, in addition.
c. The psychopathology commonly is controlled by additive buspirone for the agitation and anxiety, and/or atypical neuroleptic in low doses such as aripiprazole for the psychotic or paranoid features.
d. The cataplexy responds well to tricyclics such as nortriptyline or clomipramine (sometimes obsessionality is common).
Finally I create Table 9D , effectively a flow chart to approach the possible narcoleptic patient. c. Xyrem (oxybate), unusually, is prescribed, simply because it requires awakening at night to take a dose. Xyrem when used appears effective, and then used on its own.
d. If cataplexy: Tricyclic antidepressant like nortriptyline e.g. 50mg to 75mg daily.
The Limitations of Esoterica:
a. CSF Orexin or Hypocretin: Very rarely needed because it will just confirm what I know unless questions about etiology. Useful in research though and might lead to new drug development.
b. MSLT and /or polysomnography: Useful in unusual cases, but expensive and low-yield in our group. But do not use this to decide whether wakefulness drugs are necessary.
c. Electroencephalograms. In our experience at the PNI over 20 years, possibly one half of these patients have temporal lobe foci on extended monitoring. This contrasts with folk-lore where narcoleptic patients are supposed to have normal EEGs. If so the patients may require treatment e.g. Anticonvulsants. I clearly see a loaded population. But it is difficult for me to believe the incidence of Narcolepsy is only one in 5000 patients. I suspect maybe 90% of narcoleptic patient diagnoses are missed and if so the likelihood is the incidence is closer to 1 in 500. This marked underestimation of the narcoleptic population is also an opinion shared by Manzaneda [31] and also by Chakravorty who argues that "only 15-30% of narcoleptic individuals are ever diagnosed or treated, and nearly half first present for diagnosis after the age of 40 years [33] ."
Applying the unified approach
Classifications of old are a problem: Type 1 Narcolepsy of old is now Narcolepsy with Cataplexy. Type 2 Narcolepsy of old is now Narcolepsy without cataplexy. Fortunately, the Type 1 and Type 2 labeling seems to not be as fashionable. As indicated, I would argue for a primary narcolepsy condition and for one that is symptomatic narcolepsy due to other causes such as infection or tumor impacting hypothalamic function.
